Investors
Building towardclinical validation.
Object Pharma is advancing OP01 toward clinical development while building a differentiated neurotoxin platform designed to create multiple therapeutic opportunities.
Investor resources
Corporate presentation
The current corporate presentation and investor materials are available to qualified parties on request.
Request Investor Information